Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy is a research paper published in Journal for ImmunoTherapy of Cancer (2022). On theSindex it has a DataRank of 0. It has been cited 25 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: T32 2T32CA009657-26A1
National Cancer Institute
Grant: CA018029
National Cancer Institute
Grant: CA033084
NCI NIH HHS
Grant: R01 CA033084
NCI NIH HHS
Grant: P01 CA018029
NCI NIH HHS
Grant: P01 CA225517
NCI NIH HHS
Grant: R37 CA033084
NCI NIH HHS
Grant: T32 CA009657
National Institutes of Health
Grant: 5P01CA018029-36
Targeting Alloreactivity for Leukemia Eradication
National Institutes of Health
Grant: 5R37CA033084-15
MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY
National Institutes of Health
Grant: 2T32CA009657-26A1
Chromosome Metabolism and Cancer Training Grant
FWCI
1.89
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
Additional file 1 of CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
Additional file 2 of CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
Additional file 2 of CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality